SLS · Sellas Life Sciences Group, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $5.13M | - | $4.22M | $3.87M | $3.21M | - | $4.36M | $5.19M | $5.11M | - |
| SG&A | $2.86M | - | $2.87M | $3.00M | $2.86M | - | $2.97M | $2.44M | $4.53M | - |
| Total Operating Expenses | $9.25M | - | $7.08M | $6.87M | $6.06M | - | $7.33M | $7.62M | $9.64M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($9.25M) | - | ($7.08M) | ($6.87M) | ($6.06M) | - | ($7.33M) | ($7.62M) | ($9.64M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($8.41M) | - | ($6.79M) | ($6.60M) | ($5.81M) | - | ($7.11M) | ($7.47M) | ($9.57M) | - |
| EPS - Basic | ($0.05) | - | ($0.06) | ($0.07) | ($0.07) | - | ($0.10) | ($0.13) | ($0.21) | - |
| EPS - Diluted | ($0.05) | - | ($0.06) | ($0.07) | ($0.07) | - | ($0.10) | ($0.13) | ($0.21) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $107.10M | $71.79M | $44.32M | $25.30M | $28.40M | $13.89M | $21.03M | $9.15M | $18.41M | $2.53M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $3.63M | $2.95M | $2.31M | $3.34M | $3.76M | $3.50M | $4.55M | $6.33M | $7.41M | $5.64M |
| Current Assets | $111.17M | $75.21M | $49.05M | $29.45M | $31.97M | $16.33M | $24.04M | $12.30M | $21.50M | $3.17M |
| Total Assets | $114.18M | $78.34M | $51.55M | $32.30M | $34.96M | $19.43M | $26.50M | $15.12M | $24.43M | $6.22M |
| Current Liabilities | $6.46M | $7.02M | $5.92M | $6.00M | $6.89M | $9.51M | $10.61M | $12.04M | $14.44M | $13.73M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $6.76M | $7.47M | $5.92M | $6.16M | $7.20M | $9.97M | $10.61M | $12.21M | $14.75M | $14.20M |
| Stockholders' Equity | $107.41M | $70.87M | $45.63M | $26.15M | $27.76M | $9.46M | $15.89M | $2.91M | $9.68M | ($7.98M) |
| Retained Earnings | ($283.39M) | ($274.99M) | ($267.33M) | ($260.54M) | ($253.94M) | ($248.13M) | ($241.39M) | ($234.28M) | ($226.81M) | ($217.24M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.85M) | - | - | - | ($9.07M) | - | - | - | ($10.76M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $44.15M | - | - | - | $23.58M | - | - | - | $26.65M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -7.4% | - | -13.2% | -20.4% | -16.6% | - | -26.8% | -49.4% | -39.2% | - |
| Return on equity | -7.8% | - | -14.9% | -25.2% | -20.9% | - | -44.7% | -256.4% | -98.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 17.22 | 10.72 | 8.28 | 4.91 | 4.64 | 1.72 | 2.26 | 1.02 | 1.49 | 0.23 |
| Quick ratio | 17.22 | 10.72 | 8.28 | 4.91 | 4.64 | 1.72 | 2.26 | 1.02 | 1.49 | 0.23 |
| Cash ratio | 16.59 | 10.23 | 7.48 | 4.22 | 4.12 | 1.46 | 1.98 | 0.76 | 1.28 | 0.18 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.06 | 1.11 | 1.13 | 1.24 | 1.26 | 2.05 | 1.67 | 5.19 | 2.52 | -0.78 |
| Liabilities / Assets | 0.06 | 0.10 | 0.11 | 0.19 | 0.21 | 0.51 | 0.40 | 0.81 | 0.60 | 2.28 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 6.8x | - | 3.8x | 8.3x | 3.4x | - | 5.4x | 23.5x | 4.7x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -52.6% | - | 3.4% | 9.8% | 37.1% | - | 21.7% | 15.8% | 14.5% | - |
| Net income growth (YoY) | -44.6% | - | 4.5% | 11.6% | 39.2% | - | 23.3% | 15.5% | 13.8% | - |
| EPS growth (YoY) | 28.6% | - | 40.0% | 46.2% | 66.7% | - | 69.7% | 58.1% | 55.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 286.9% | 648.8% | 187.1% | 797.7% | 186.6% | - | - | -39.9% | -26.5% | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing SELLAS Life Sciences Group against the 5 most active filers in the same SIC group.